skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Lapatinib (Code C26653)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lapatinib

Definition: A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.

NCI-GLOSS Definition: A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.

Label: Lapatinib

NCI Thesaurus Code: C26653 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1506770  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
GW 2016

External Source Codes: 
CAS Registry Number 231277-92-2 (see NLM ChemIDplus info)
FDA UNII Code 0VUA21238F
ChEBI ID CHEBI:49603 (see ChEBI info)
NSC Code 727989 (see NCI DTP info)
PubMedID Primary Reference 12214266 (see PubMed Primary Reference info)
UMLS CUI C1506770

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C29H26ClFN4O4S
code C26653
Contributing_Source FDA
Legacy_Concept_Name GW572016
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom